Monthly Archives: February 2012
Rare Disease Day: Spotlight on Solidarity
Patients, policymakers and pharmaceutical companies are uniting around rare diseases on the rarest of calendar days, presaging a leap forward in health outcomes and business opportunities.
Aligning humanistic objectives with business incentives is often the sine qua non of effective community activism. This year’s Rare Disease Day – hosted in the US by the National [...]
Posted in Events, FDA, Global, Patient Communication, Strategy, healthcare, leadership, patient education, social media Tagged FDA, NIH, NORD, orphan diseases, patient groups, patient information, Rare Disease Day, rare diseases Leave a comment
Onyx Bullish in 2012 Outlook
With an all-important FDA decision on carfilzomib scheduled for July 27, Onyx hopes to graduate to the next stage of commercial success. For a feature-length profile of Onyx and CEO Tony Coles, click here.
Following on a strong 4Q report, Onyx Pharmaceuticals’ CEO Tony Coles said the company hopes to transform itself from a one-product [...]
Posted in FDA, Market Access, People, R&D, Regulatory, Strategy, pricing Tagged carfilzomib, Earnings, forecast, Onyx Pharmaceuticals Leave a comment
Combating Opioid Abuse With Science
So far, the creative approaches industry has taken to develop tamper-resistant and abuse-deterrent opioid drugs have been largely matched by the ingenuity of those users who manage to tamper with and abuse those same formulations.
Posted in FDA, R&D, Regulatory, Safety, Strategy, Technology Tagged drug safety, FDA, new molecular entities, opioids 3 Comments
Tasty Asian Acquisition for Publicis
Publicis Healthcare Gobbles Up Another Asian Agency
Publicis continues its expansion into Asia with today’s (Feb 20) announcement of its acquisition of U-Link Business Solutions (UBS), one of China’s leading agencies specializing in healthcare communications.
As a part of Publicis Healthcare Communications Group, the agency will be renamed UBS Saatchi & Saatchi Health.
“The Chinese healthcare market is [...]
Posted in Agency Insight, Emerging Markets, Global, Guest Blog Tagged acquisition, China, Emerging Markets, healthcare agencies, Publicis Healthcare Leave a comment

Rare Diseases Lead to Unique Legislation